The prevalence of ascariasis in COPD patients with and without concomitant pulmonary aspergillosis and in controls will be determined. To assess the influence of ascaridosis on the development of pulmonary aspergillosis in COPD patients cytokine status of patients will be studied.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
200
Level of serum interleukin-1B will be detected
Level of serum interleukin-4 will be detected
Level of serum interleukin-4 will be detected
Research institute of epidemiology, microbiology and infectious diseases
Tashkent, Uchtepa, Uzbekistan
RECRUITINGSerum interleukin-1B levels in COPD patients and controls
Serum interleukin-1B (pg/mL) levels will be measured in COPD patients without concomitant infection, COPD patients with pulmonary aspergillosis, COPD patients with ascariasis, COPD patients with ascariasis and pulmonary aspergillosis, and healthy individuals.
Time frame: up to 12 months
Serum interleukin-4 levels in COPD patients and controls
Serum interleukin-4 (pg/mL) levels will be measured in COPD patients without concomitant infection, COPD patients with pulmonary aspergillosis, COPD patients with ascariasis, COPD patients with ascariasis and pulmonary aspergillosis, and healthy individuals.
Time frame: up to 12 months
Serum interleukin-6 levels in COPD patients and controls
Serum interleukin-6 (pg/mL) levels will be measured in COPD patients without concomitant infection, COPD patients with pulmonary aspergillosis, COPD patients with ascariasis, COPD patients with ascariasis and pulmonary aspergillosis, and healthy individuals.
Time frame: up to 12 months
Serum tumor necrosis factor-a levels in COPD patients and controls
Serum tumor necrosis factor-a (pg/mL) levels will be measured in COPD patients without concomitant infection, COPD patients with pulmonary aspergillosis, COPD patients with ascariasis, COPD patients with ascariasis and pulmonary aspergillosis, and healthy individuals.
Time frame: up to 12 months
Serum interferon-gamma levels in COPD patients and controls
Serum interferon-gamma (pg/mL) levels will be measured in COPD patients without concomitant infection, COPD patients with pulmonary aspergillosis, COPD patients with ascariasis, COPD patients with ascariasis and pulmonary aspergillosis, and healthy individuals.
Time frame: up to 12 months
Correlation between cytokine status with chronic pulmonary aspergilosis insidence rate in COPD patients with and without ascariasis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Level of serum tumor necrosis factor - a will be detected
Level of serum interferon- gamma will be detected
The correlation between serum interleukin-1B, interleukin-4, interleukin-6, tumor necrosis factor-a and interferon-y levels with chronic pulmonary aspergilosis insidence rate in COPD patients with and without ascariasis will be assessed.
Time frame: up to 12 months
Rate of ascariasis infestation among COPD patients and controls
The frequency of ascariasis infestation among COPD patients with and without pulmonary aspergillosis, as well as healthy individuals, will be assessed.
Time frame: up to 12 months